Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHunger on Wegovy is more common than most people expect, and it rarely means the medicine isn't working. Semaglutide reduces appetite by acting on GLP-1 receptors in the brain and gut, but appetite suppression varies by dose, by person, and by what you eat. These are prescription-only medicines requiring clinical assessment before any treatment decision is made.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most people starting Wegovy expect their appetite to disappear quickly. When it doesn't, the instinct is to assume something has gone wrong. That assumption is almost always wrong. The 0.25mg and 0.5mg starting doses are titration steps designed to let your body adjust, they are not intended to produce the full appetite effect. Appetite suppression deepens with each escalation, typically reaching meaningful levels around the 1.7mg and 2.4mg maintenance doses. Feeling hungry during the early weeks is the treatment working as designed, not failing.
There is also a useful distinction between physiological hunger (your body genuinely needs fuel) and what many patients describe as 'food noise', the persistent, intrusive pull towards eating that has nothing to do with calories. Semaglutide tends to quiet food noise more reliably than it eliminates physical hunger, particularly at lower doses. If you are curious how Wegovy acts on these two different systems, our page on Wegovy and food noise covers this in detail. The NHS's medicines information for semaglutide confirms that appetite-related effects vary between individuals and build over the titration period. The NHS semaglutide medicines page is a good reference for what the expected side-effect and benefit profile looks like across the full dose schedule.
Understanding this distinction tends to reduce a lot of the anxiety around early hunger. It shifts the question from 'is this broken?' to 'what can I do to support the medicine while it builds?'
Even at maintenance doses, certain patterns reliably undermine the appetite-reduction effect. The most common is low protein intake. Semaglutide slows gastric emptying, which means food stays in the stomach longer, but only if that food has enough bulk and density to take advantage of the effect. A small, carbohydrate-heavy snack digests quickly, leaves the stomach fast, and leaves you hungry again within an hour or two. A meal anchored by protein and fibre keeps the stomach fuller for longer and works with the medicine rather than around it.
Hydration matters too. Mild dehydration produces a sensation that is easy to read as hunger, and people on semaglutide sometimes drink less because their appetite signals are generally quieter. Eating very quickly (before the brain has received the 'full' signal, which takes around 20 minutes) is another overlooked factor. Practical guidance on what to eat on Wegovy sets out the food patterns that support the medicine most effectively, including protein targets and meal-structure ideas.
Timing within the weekly dose cycle also plays a role. Some people notice hunger creeping back in days five, six or seven before the next injection. This is physiologically normal, the active concentration of semaglutide in the blood gradually falls across the week. A closer look at hunger patterns across the Wegovy dose cycle explores this in more detail. If this end-of-week effect is significant, it's a conversation worth having with your prescriber: for some people, adjusting the day of injection makes a difference.
Hunger that does not ease as your dose increases, or that is severe enough to make it hard to keep to a reduced-calorie diet, is not something to simply push through. It can indicate that the current dose is not yet therapeutic for you, that an underlying factor (such as poor sleep, high stress levels, or thyroid function) is overriding the appetite effect, or simply that the dietary pattern needs adjustment. None of these are things a forum or an article can resolve, they need a prescriber who knows your full picture.
This is one of the questions our prescribers at our clinical team hear most often from people who are a few weeks into treatment. If you are already on Wegovy through another provider and wondering whether your experience is typical, more on persistent hunger at a stable Wegovy dose addresses the specific scenario where hunger has not settled even after reaching your maintenance dose. There is also a parallel experience on semaglutide more broadly, why hunger persists on semaglutide covers the mechanism from a slightly different angle that some readers find useful.
It is also worth knowing that weight-loss medicines like Wegovy are prescription-only for exactly this reason. The titration schedule, the dietary support, and the response monitoring are all part of the clinical picture, not optional extras. The NICE appraisal of semaglutide for weight management (TA875) specifically recommends that treatment is delivered alongside structured diet and lifestyle support, which is the framework most likely to reduce the hunger that people experience mid-treatment.
If you have questions about starting a clinically supervised programme, our Wegovy overview covers the full treatment picture, and you can find out more about what the process involves on our weight-loss treatments page.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.